|
|
||||||||||
|
J Am Coll Cardiol, 2004; 44:2339-2348, doi:10.1016/j.jacc.2004.09.041 © 2004 by the American College of Cardiology Foundation |


* Cardiopulmonary Laboratory, Cardiology Division, University of Milano, San Paolo Hospital, Milan, Italy
Respiratory Unit, University of Milano, San Paolo Hospital, Milan, Italy
Institute of Cardiology, University of Milano, Milan, Italy
Manuscript received June 25, 2004; revised manuscript received August 27, 2004, accepted September 6, 2004.
* Reprint requests and correspondence: Dr. Marco Guazzi, Cardiopulmonary Laboratory, University of Milano, Cardiology Division, San Paolo Hospital, Via A. di Rudini, 8, 20142 Milano, Italy (Email: Marco.Guazzi{at}unimi.it).
Presented, in part, at the 76th American Heart Association Scientific Sessions, Orlando, Florida, November 9 to 12, 2003.
OBJECTIVES: We sought to investigate the effects of sildenafil, a phosphodiesterase-5 (PDE5) inhibitor, on lung function and exercise performance in chronic heart failure (CHF).
BACKGROUND: In CHF, nitric oxide-mediated regulation of lung vascular tone and alveolar-capillary membrane conductance is impaired and contributes to exercise intolerance. The potential for benefits due to increased nitric-oxide availability is unexplored.
METHODS: In 16 patients with CHF and 8 normal subjects, we measuredbefore and 60 min after sildenafil (50 mg) or placeboejection fraction, pulmonary hemodynamics, carbon monoxide diffusion capacity (DLco), with its membrane (DM) and capillary blood volume (Vc) subcomponents, endothelial function (brachial reactive hyperemia) at rest, peak oxygen uptake (VO2), increments in VO2 versus work rate (
VO2/
WR), changes in ventilation versus CO2 production (VE/VCO2) slope, and recovery VO2 time constant (tau) on exertion.
RESULTS: In CHF, sildenafil did not affect cardiac index, wedge pulmonary pressure, or ejection fraction; it significantly (p < 0.01) decreased pulmonary mean artery pressure (20.4%) and arteriolar resistance (45.1%), VE/VCO2 slope (9.0%) and recovery tau (25.8%), and increased (p < 0.01) DLco (+11.1%), DM (+9.9%) peak VO2 (+19.7%),
VO2/
WR (+11.0%), and brachial reactive hyperemia (+33.3%). No variations occurred in normal subjects and after placebo. Changes in DLco were related to those in VE/VCO2 slope (r = 0.71; p = 0.002), and changes in brachial hyperemia correlated with those in
VO2/
WR (r = 0.80; p = 0.0002).
CONCLUSIONS: This study shows that in CHF PDE5 inhibition modulates pulmonary pressure and vascular tone, and improves DLco, exercise peak VO2, aerobic (
VO2/
WR) and ventilatory (VE/VCO2 slope) efficiencies, and oxygen debt (recovery tau). Endothelial mechanisms may underlie these effects.
| |||||||||||||||
This article has been cited by other articles:
![]() |
A. Giardini, A. Balducci, S. Specchia, G. Gargiulo, M. Bonvicini, and F. M. Picchio Effect of sildenafil on haemodynamic response to exercise and exercise capacity in Fontan patients Eur. Heart J., July 1, 2008; 29(13): 1681 - 1687. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Guazzi, R. Arena, and M. D. Guazzi Evolving changes in lung interstitial fluid content after acute myocardial infarction: mechanisms and pathophysiological correlates Am J Physiol Heart Circ Physiol, March 1, 2008; 294(3): H1357 - H1364. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. N. Salloum, A. Abbate, A. Das, J.-E. Houser, C. A. Mudrick, I. Z. Qureshi, N. N. Hoke, S. K. Roy, W. R. Brown, S. Prabhakar, et al. Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice Am J Physiol Heart Circ Physiol, March 1, 2008; 294(3): H1398 - H1406. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Guazzi, M. Samaja, R. Arena, M. Vicenzi, and M. D. Guazzi Long-Term Use of Sildenafil in the Therapeutic Management of Heart Failure J. Am. Coll. Cardiol., November 27, 2007; 50(22): 2136 - 2144. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. Goldsmith Type 5 Phosphodiesterase Inhibition in Heart Failure: The Next Step J. Am. Coll. Cardiol., November 27, 2007; 50(22): 2145 - 2147. [Full Text] [PDF] |
||||
![]() |
D. A. Kass, H. C. Champion, and J. A. Beavo Phosphodiesterase Type 5: Expanding Roles in Cardiovascular Regulation Circ. Res., November 26, 2007; 101(11): 1084 - 1095. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. D. Lewis, R. Shah, K. Shahzad, J. M. Camuso, P. P. Pappagianopoulos, J. Hung, A. Tawakol, R. E. Gerszten, D. M. Systrom, K. D. Bloch, et al. Sildenafil Improves Exercise Capacity and Quality of Life in Patients With Systolic Heart Failure and Secondary Pulmonary Hypertension Circulation, October 2, 2007; 116(14): 1555 - 1562. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Tumminello, M. Guazzi, P. Lancellotti, and L. A. Pierard Exercise ventilation inefficiency in heart failure: pathophysiological and clinical significance Eur. Heart J., March 2, 2007; 28(6): 673 - 678. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. D. Lewis, J. Lachmann, J. Camuso, J. J. Lepore, J. Shin, M. E. Martinovic, D. M. Systrom, K. D. Bloch, and M. J. Semigran Sildenafil Improves Exercise Hemodynamics and Oxygen Uptake in Patients With Systolic Heart Failure Circulation, January 2, 2007; 115(1): 59 - 66. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Agostoni, M. Bussotti, G. Cattadori, E. Margutti, M. Contini, M. Muratori, G. Marenzi, and C. Fiorentini Gas diffusion and alveolar-capillary unit in chronic heart failure Eur. Heart J., November 1, 2006; 27(21): 2538 - 2543. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. N. DeMaria, O. Ben-Yehuda, D. Berman, G. K. Feld, B. H. Greenberg, J. D. Knoke, K. U. Knowlton, W. Y.W. Lew, J. Narula, D. Sahn, et al. Highlights of the year in JACC 2004 J. Am. Coll. Cardiol., January 4, 2005; 45(1): 137 - 153. [Full Text] [PDF] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |